Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06837246 · ClinicalTrials.gov registry record · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
A NA study of Cognition and Attention, sponsored by Pharmavite.
- Recruiting
- Registry status
- NA
- Development phase
- 422
- Enrollment target
- 1
- Study location
NCT06837246: Recruiting NA study of Cognition and Attention, sponsored by Pharmavite.
NCT06837246 is a NA study of Cognition and Attention that is actively recruiting participants, run by Pharmavite. The registered enrollment target is 422 participants, above the 160-participant average among 35 other Cognition trials with a reported enrollment target (164% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06837246, a NA study of Cognition and Attention, is actively recruiting participants, sponsored by Pharmavite.
- RECRUITING
- Registry status
- NA
- Development phase
- 422 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention/focus related domains, compared to a placebo control, in a general population of adult men and women in the United States.
Primary Outcome
Overall Score: The sum of the difficulties of all successfully answered problems, minus the sum of the difficulties of all incorrectly answered problems
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Cognitive Nutritional Supplement
Study Locations (1)
Illinois
- Biofortis Innovation Services - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What NCT06837246 shows while recruiting
NCT06837246 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, above the 160-participant average among 35 other Cognition trials with a reported enrollment target (164% higher).
The record links to 4 conditions, with Cognition appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06837246 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06837246 about?
NCT06837246 is a clinical study titled "A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population". This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention/focus related domains, compared to a placebo control, in a general population of adult men and women in the U...
What is the current status of trial NCT06837246?
This trial is currently recruiting. It is a NA study. The enrollment target is 422 participants. The study started on 2025-02-24. Estimated completion is 2025-09-30.
What conditions does trial NCT06837246 study?
This clinical trial studies the following conditions: Cognition, Attention, Focus, Concentration.
What interventions are being tested in trial NCT06837246?
The interventions under investigation include: Placebo (OTHER), Cognitive Nutritional Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06837246?
This trial is sponsored by Pharmavite, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06837246 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06837246's enrollment target sits among peer trials
422 4th of 35 higher than 32 of 35 other Cognition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults
RECRUITING · NA
-
Nutrition to Support Postoperative Recovery
RECRUITING · NA
-
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
RECRUITING · NA
-
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
RECRUITING · NA
-
Identifying the Neural Correlates of Mental Simulation in Multi-Step Planning
RECRUITING · NA
-
Sleep Well Firefighters: An App-based Program to Improve Sleep, Cognition, and Behavioral Health in Firefighters
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI